Literature DB >> 17544965

Erythema nodosum leprosum: reactional leprosy.

Jesús Cuevas1, José Luis Rodríguez-Peralto, Rosario Carrillo, Félix Contreras.   

Abstract

The different clinical forms of leprosy are mainly related to the variety of immunological responses to the infection. Thus, lepromatous leprosy occurs in patients with a poor cell-mediated immunity to Mycobacterium leprae, whereas tuberculoid leprosy is associated with a high resistance to leprosy bacillus. Intermediate forms, including borderline tuberculoid leprosy, borderline lepromatous leprosy, and borderline leprosy, are a continuous and unstable spectrum of the disease. Leprosy reactions are rare and not well-known states that interrupt the usual chronic course and clinical stability of patients with leprosy. They are expressions of immunological perturbations. Attending to the clinical and histopathological manifestations, leprosy reactions may be separated in 2 or 3 different variants: reverse reaction (type I), erythema nodosum leprosum (type II), erythema polymorphous (type II) and Lucio's phenomenon, mainly considered a type II reaction, but sometimes designated type III. Type I leprosy reaction, also named "upgrading reaction," occurs in borderline leprosy states and is associated with a shift toward the tuberculoid pole. Type II reaction usually occurs in lepromatous leprosy, and there are 3 different clinical variants, including erythema nudosum leprosum, erythema polymorphous-like reaction, and Lucio's phenomenon.

Entities:  

Mesh:

Year:  2007        PMID: 17544965     DOI: 10.1016/j.sder.2007.02.010

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  15 in total

Review 1.  Lucio's phenomenon: report of five cases.

Authors:  Pablo Finucci Curi; Julieta Solis Villaroel; Nora Migliore; Adriana Albertengo; María Laura Aquino; Federico Ceccato; Sergio Paira
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

2.  Cutaneous leprosy in Central Florida man with significant armadillo exposure.

Authors:  Christopher Michael Logas; Kathryn B Holloway
Journal:  BMJ Case Rep       Date:  2019-06-29

3.  Mycobacterium leprae actively modulates the cytokine response in naive human monocytes.

Authors:  Daniel Sinsimer; Dorothy Fallows; Blas Peixoto; James Krahenbuhl; Gilla Kaplan; Claudia Manca
Journal:  Infect Immun       Date:  2009-10-19       Impact factor: 3.441

4.  Mycobacterium tuberculosis infection is associated with the development of erythema nodosum and nodular vasculitis.

Authors:  Sheng'an Chen; Jiazhen Chen; Lianjun Chen; Qiao'an Zhang; Xiaoqun Luo; Wenhong Zhang
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

5.  Quality of life in patients with erythema nodosum leprosum in Kuala Lumpur, Malaysia.

Authors:  Felix B Yap; Sze T Kiung; Jeffrey B Yap
Journal:  Indian Dermatol Online J       Date:  2016 Jul-Aug

6.  Leprosy reactions: coinfections as a possible risk factor.

Authors:  Ana Carolina F Motta; Karla Juliana Pereira; Daniela Chaves Tarquínio; Mariana Bellini Vieira; Karina Miyake; Norma Tiraboschi Foss
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

Review 7.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

8.  Leprosy Reaction in Thai Population: A 20-Year Retrospective Study.

Authors:  Poonkiat Suchonwanit; Siripich Triamchaisri; Sanchawan Wittayakornrerk; Ploysyne Rattanakaemakorn
Journal:  Dermatol Res Pract       Date:  2015-10-05

9.  The +3187A/G HLA-G polymorphic site is associated with polar forms and reactive reaction in leprosy.

Authors:  N Lucena-Silva; M A G Teixeira; A de L Ramos; R S de Albuquerque; G T N Diniz; C T Mendes-Junior; E C Castelli; E A Donadi
Journal:  Mol Genet Genomic Med       Date:  2013-06-07       Impact factor: 2.183

Review 10.  Leprosy in Denmark 1980-2010: a review of 15 cases.

Authors:  Huma Aftab; Susanne D Nielsen; Ib C Bygbjerg
Journal:  BMC Res Notes       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.